{"id":71688,"date":"2026-08-05T01:04:24","date_gmt":"2026-08-04T17:04:24","guid":{"rendered":"https:\/\/flcube.com\/?p=71688"},"modified":"2026-08-05T01:04:25","modified_gmt":"2026-08-04T17:04:25","slug":"abbvie-reports-10-2-revenue-growth-in-q2-2026-driven-by-strong-immunology-performance","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=71688","title":{"rendered":"AbbVie Reports 10.2% Revenue Growth in Q2 2026, Driven by Strong Immunology Performance"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>AbbVie<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/ABBV:NYSE\">NYSE: ABBV<\/a>) announced financial results for the second quarter (Q2) of 2026.<\/p>\n\n\n\n<h2 id=\"h-financial-performance-summary\" class=\"wp-block-heading\">Financial Performance Summary<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>Q2 2026<\/th><th>Change<\/th><\/tr><\/thead><tbody><tr><td><strong>Worldwide Net Revenues<\/strong><\/td><td>USD 16.990 billion<\/td><td>+10.2%<\/td><\/tr><tr><td><strong>Adjusted Diluted EPS Guidance (Full Year 2026)<\/strong><\/td><td>USD 13.87 &#8211; USD 14.07<\/td><td>Updated from USD 13.91 &#8211; USD 14.11<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-business-segment-performance\" class=\"wp-block-heading\">Business Segment Performance<\/h2>\n\n\n\n<h3 id=\"h-immunology-portfolio\" class=\"wp-block-heading\">Immunology Portfolio<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Total Revenue<\/strong>: USD 8.786 billion (+15.1%)<\/li>\n\n\n\n<li><strong>Skyrizi (Risankizumab)<\/strong>: USD 5.505 billion (+24.4%)<\/li>\n\n\n\n<li><strong>Rinvoq (Upadacitinib)<\/strong>: USD 2.525 billion (+24.5%)<\/li>\n\n\n\n<li><strong>Humira (Adalimumab)<\/strong>: USD 756 million (+35.9%)<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-neuroscience-portfolio\" class=\"wp-block-heading\">Neuroscience Portfolio<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Total Revenue<\/strong>: USD 3.228 billion (+20.3%)<\/li>\n\n\n\n<li><strong>Vraylar (Cariprazine)<\/strong>: USD 1.071 billion (+18.9%)<\/li>\n\n\n\n<li><strong>Botox Therapeutic<\/strong>: USD 1.042 billion (+12.2%)<\/li>\n\n\n\n<li><strong>Ubrelvy (Ubrogepant)<\/strong>: USD 392 million (+16.0%)<\/li>\n\n\n\n<li><strong>Qulipta (Atogepant)<\/strong>: USD 350 million (+30.9%)<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-oncology-portfolio\" class=\"wp-block-heading\">Oncology Portfolio<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Total Revenue<\/strong>: USD 1.650 billion (-1.5%)<\/li>\n\n\n\n<li><strong>Venclexta (Venetoclax)<\/strong>: USD 771 million (+11.6%)<\/li>\n\n\n\n<li><strong>Imbruvica (Ibrutinib)<\/strong>: USD 532 million (-29.4%)<\/li>\n\n\n\n<li><strong>Elahere (Mirvetuximab Soravtansine)<\/strong>: USD 211 million (+33.1%)<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-aesthetics-portfolio\" class=\"wp-block-heading\">Aesthetics Portfolio<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Total Revenue<\/strong>: USD 1.282 billion (+0.3%)<\/li>\n\n\n\n<li><strong>Botox Cosmetic<\/strong>: USD 728 million (+5.2%)<\/li>\n\n\n\n<li><strong>Juvederm<\/strong>: USD 245 million (-6.0%)<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-significance\" class=\"wp-block-heading\">Strategic Significance<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">AbbVie&#8217;s Q2 2026 performance demonstrates the company&#8217;s successful diversification strategy beyond its legacy Humira franchise. The immunology portfolio continues to show exceptional growth with a 15.1% increase, driven by strong performances from next-generation assets Skyrizi and Rinvoq, which collectively generated USD 8.03 billion in revenue.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The neuroscience portfolio showed robust 20.3% growth, highlighting AbbVie&#8217;s expanding presence in this therapeutic area. While the oncology portfolio experienced a slight 1.5% decline overall, newer assets like Elahere (+33.1%) and Venclexta (+11.6%) demonstrated strong growth, partially offsetting the decline in Imbruvica.<\/p>\n\n\n\n<h2 id=\"h-updated-full-year-guidance\" class=\"wp-block-heading\">Updated Full-Year Guidance<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">To include the impact of the proposed Apogee Therapeutics acquisition, AbbVie is updating its adjusted diluted EPS guidance range for the full year 2026 from USD 13.91 &#8211; USD 14.11 to USD 13.87 &#8211; USD 14.07.<\/p>\n\n\n\n<h2 id=\"h-market-context-amp-competitive-positioning\" class=\"wp-block-heading\">Market Context &amp; Competitive Positioning<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Immunology Leadership<\/strong>: AbbVie maintains dominant market position with continued strong growth in Skyrizi and Rinvoq<\/li>\n\n\n\n<li><strong>Portfolio Diversification<\/strong>: Successful expansion into neuroscience and aesthetics reduces dependency on any single therapeutic area<\/li>\n\n\n\n<li><strong>Oncology Transition<\/strong>: Managing the transition from mature assets like Imbruvica to next-generation therapies<\/li>\n\n\n\n<li><strong>Strategic Acquisitions<\/strong>: Proposed Apogee Therapeutics acquisition reflects commitment to pipeline innovation<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-company-statement\" class=\"wp-block-heading\">Company Statement<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">&#8220;Our second quarter results reflect the strength of our diversified portfolio and our ability to execute across multiple therapeutic areas,&#8221; said Robert A. Michael, Chief Executive Officer of AbbVie. &#8220;The exceptional performance of our immunology franchise, combined with strong growth in neuroscience and promising early data from our pipeline, positions us well for sustained long-term growth.&#8221;<\/p>\n\n\n\n<h2 id=\"h-forward-looking-statements\" class=\"wp-block-heading\">Forward-Looking Statements<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">This brief contains forward-looking statements regarding financial performance, growth expectations, business outlook, and the proposed Apogee Therapeutics acquisition. Actual results may differ due to market dynamics, competitive pressures, regulatory developments, integration risks, and other risk factors.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/ABBV_2Q26_Press_Release_Final.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of ABBV_2Q26_Press_Release_Final.\"><\/object><a id=\"wp-block-file--media-7a552574-5072-4894-8c27-551f0b9bde81\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/ABBV_2Q26_Press_Release_Final.pdf\">ABBV_2Q26_Press_Release_Final<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/ABBV_2Q26_Press_Release_Final.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-7a552574-5072-4894-8c27-551f0b9bde81\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>AbbVie (NYSE: ABBV) announced financial results for the second quarter (Q2) of 2026. Financial Performance&#8230;<\/p>\n","protected":false},"author":1,"featured_media":71690,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7],"tags":[234,27,853],"class_list":["post-71688","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-abbvie","tag-finanical-reports","tag-nyse-abbv"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>AbbVie Reports 10.2% Revenue Growth in Q2 2026, Driven by Strong Immunology Performance - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"AbbVie (NYSE: ABBV) announced financial results for the second quarter (Q2) of 2026.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=71688\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AbbVie Reports 10.2% Revenue Growth in Q2 2026, Driven by Strong Immunology Performance\" \/>\n<meta property=\"og:description\" content=\"AbbVie (NYSE: ABBV) announced financial results for the second quarter (Q2) of 2026.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=71688\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-04T17:04:24+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-04T17:04:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/0406.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71688#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71688\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"AbbVie Reports 10.2% Revenue Growth in Q2 2026, Driven by Strong Immunology Performance\",\"datePublished\":\"2026-08-04T17:04:24+00:00\",\"dateModified\":\"2026-08-04T17:04:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71688\"},\"wordCount\":410,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71688#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/0406.webp\",\"keywords\":[\"AbbVie\",\"Finanical Reports\",\"NYSE: ABBV\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=71688#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71688\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=71688\",\"name\":\"AbbVie Reports 10.2% Revenue Growth in Q2 2026, Driven by Strong Immunology Performance - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71688#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71688#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/0406.webp\",\"datePublished\":\"2026-08-04T17:04:24+00:00\",\"dateModified\":\"2026-08-04T17:04:25+00:00\",\"description\":\"AbbVie (NYSE: ABBV) announced financial results for the second quarter (Q2) of 2026.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71688#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=71688\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71688#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/0406.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/0406.webp\",\"width\":1080,\"height\":608,\"caption\":\"AbbVie Reports 10.2% Revenue Growth in Q2 2026, Driven by Strong Immunology Performance\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71688#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AbbVie Reports 10.2% Revenue Growth in Q2 2026, Driven by Strong Immunology Performance\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"AbbVie Reports 10.2% Revenue Growth in Q2 2026, Driven by Strong Immunology Performance - Insight, China&#039;s Pharmaceutical Industry","description":"AbbVie (NYSE: ABBV) announced financial results for the second quarter (Q2) of 2026.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=71688","og_locale":"en_US","og_type":"article","og_title":"AbbVie Reports 10.2% Revenue Growth in Q2 2026, Driven by Strong Immunology Performance","og_description":"AbbVie (NYSE: ABBV) announced financial results for the second quarter (Q2) of 2026.","og_url":"https:\/\/flcube.com\/?p=71688","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-04T17:04:24+00:00","article_modified_time":"2026-08-04T17:04:25+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/0406.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=71688#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=71688"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"AbbVie Reports 10.2% Revenue Growth in Q2 2026, Driven by Strong Immunology Performance","datePublished":"2026-08-04T17:04:24+00:00","dateModified":"2026-08-04T17:04:25+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=71688"},"wordCount":410,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=71688#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/0406.webp","keywords":["AbbVie","Finanical Reports","NYSE: ABBV"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=71688#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=71688","url":"https:\/\/flcube.com\/?p=71688","name":"AbbVie Reports 10.2% Revenue Growth in Q2 2026, Driven by Strong Immunology Performance - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=71688#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=71688#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/0406.webp","datePublished":"2026-08-04T17:04:24+00:00","dateModified":"2026-08-04T17:04:25+00:00","description":"AbbVie (NYSE: ABBV) announced financial results for the second quarter (Q2) of 2026.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=71688#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=71688"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=71688#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/0406.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/0406.webp","width":1080,"height":608,"caption":"AbbVie Reports 10.2% Revenue Growth in Q2 2026, Driven by Strong Immunology Performance"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=71688#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"AbbVie Reports 10.2% Revenue Growth in Q2 2026, Driven by Strong Immunology Performance"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/0406.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/71688","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=71688"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/71688\/revisions"}],"predecessor-version":[{"id":71691,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/71688\/revisions\/71691"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/71690"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=71688"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=71688"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=71688"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}